Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 5 of 5 publications.

Awan FT, Yande S, Esterberg L, Nagar SP, Goyal RK, Priyadarshini M. Economic burden in patients (pt) with CLL/SLL (CLL) who received ≥ 2 prior lines of therapy (LOT), including a Bruton tyrosine kinase inhibitor (BTKi): a SEER-Medicare analysis. Poster presented at the ASCO Quality Care Symposium 2023; October 27, 2023. Boston, MA. [abstract] JCO Oncol Pract. 2023 Nov 1; 19(11 Suppl):23-4. doi: 10.1200/OP.2023.19.11_suppl.24

Gnanasakthy A, Norcross L, Clark M, Fitzgerald K. A review of patient-reported outcome considerations in oncologic drug advisory committee meetings (2016-2021). JCO Oncol Pract. 2023 May;19(5):e745-62. doi: 10.1200/OP.22.00774

Mahmoudi E, Lin P, Khan A, Kamdar N, Peterson MD. Potentially preventable hospitalizations among adults with pediatric-onset disabilities. Mayo Clin Proc. 2022 Dec;97(12):2226-35. doi: 10.1016/j.mayocp.2022.07.026.

Lopez LR, Barlogio CJ, Broberg CA, Wang J, Arthur JC. A nadA mutation confers nicotinic acid auxotrophy in pro-carcinogenic intestinal escherichia coli NC101. Front Microbiol. 2021 Jun 2;12:670005. doi: 10.3389/fmicb.2021.670005

Mintz ML, Yawn BP, Mannino DM, Donohue JF, Hanania NA, Grellet CA, Gilsenan AW, McLeod LD, Dalal AA, Raphiou IH, Prillaman BA, Crater GD, Cicale MJ, Mapel DW. Prevalence of airway obstruction assessed by lung function questionnaire. Mayo Clin Proc. 2011 May 1;86(5):375-81.